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SUMMARY 
 
Sleep and wakefulness are active processes controlled by multiple neuronal circuits 
in the brain.  The most recently identified wakefulness-promoting area of the brain resides in 
the perifornical area of the lateral hypothalamus (LH) where cells are producing the peptide 
orexin.  Mounting evidence indicates the importance of orexin in the regulation of 
wakefulness.  Orexin neurons are, however, shared by another neuronal network that also 
involves ghrelin and neuropeptide Y (NPY) signaling mechanisms.  The role of the 
hypothalamic ghrelin – NPY – orexin circuit in feeding is well-established, the activation of 
the circuit leads to increased food intake while the inhibition results in decreased eating.  
Substantial evidence supports the notion that the regulation of sleep/wakefulness and 
feeding/metabolism are linked and coordinated by shared neuronal circuits in the brain.  We 
hypothesize that the neuronal network, formed by ghrelin – NPY – orexin cells in the 
hypothalamus is one of these mechanisms.  In the present experiments we studied the role of 
the hypothalamic ghrelin – NPY – orexin circuit in sleep by determining the diurnal rhythms 
of plasma and hypothalamic ghrelin levels, the dependency of these rhythms on sleep-wake 
activity and the sleep-wake activity-modulating effects of central injections of ghrelin and 
NPY in rats. 
We found that plasma and hypothalamic ghrelin levels display marked diurnal 
rhythms associated with feeding and sleep-wake activity.  Food restriction to the light period 
reverses REMS and plasma ghrelin rhythms whereas sleep deprivation increases plasma and 
hypothalamic ghrelin levels.  Intracerebroventricular (icv) injection of ghrelin induces dose-
dependent and immediate increases in wakefulness, food intake and feeding behavior, with the 
concomitant suppressions of non-rapid-eye movement sleep and rapid-eye movement sleep.  
Microinjections of ghrelin into the LH, medial preoptic area or paraventricular nucleus mimic 
the effects of the icv ghrelin treatment.  The effects of icv and intra-LH injections of NPY on 
sleep and food intake are similar to those of ghrelin’s. 
The first hours of the dark, behaviorally active, period in rats are characterized by 
increased time spent awake and increased eating activity.  We named this behavioral pattern 
“dark onset syndrome”.  Central administration of ghrelin or NPY elicits all components of the 
dark onset syndrome.  We hypothesize that the hypothalamic ghrelin – NPY - orexin circuit is 
a major brain center that integrates information about the energy status of the body through 
metabolic, circadian and visual signals.  The activation of the circuit has two main parallel 
outputs: increased wakefulness and increased feeding activity.  
 2 
INTRODUCTION 
 
Sleep is an essential biological process, a periodical, reversible state characterized 
by reduced motility, stereotypic posture and decreased responsiveness to sensory stimuli.  
Sleep and sleep-associated pathologies affect our physical and mental well-being, productivity 
and safety.  Even in the most primitive animals, rest-activity rhythms can be observed.  In 
mammals and birds, three types of vigilance states can be distinguished by 
electroencephalogram (EEG), i.e., wake, rapid-eye movement sleep (REMS) and non-rapid-
eye movement sleep (NREMS).  These states are fundamentally different in terms of 
regulation and associated physiological, neurological, and psychological features. 
 
The neuronal pathways that promote arousal 
 
In the first half of the 20th century, the landmark observations of von Economo, 
Moruzzi and Magoun provided the first evidence for a neurological basis for wakefulness and 
arousal.  Today, the general consensus is that sleep and wakefulness are active processes the 
timing and duration of which are controlled by neuronal circuits in the brain.  The brain 
contains multiple wakefulness-promoting centers that reside in the brainstem, thalamus, 
hypothalamus and basal forebrain.  From these structures, ascending pathways projecting to 
the cerebral cortex to stimulate cortical activation and descending networks acting upon the 
spinal cord to stimulate sensory-motor responsiveness and activity arise.  Various 
neurotransmitters and/or neuromodulators are produced and utilized to convey information 
among the centers.  An important characteristic of the wakefulness-promoting system of the 
brain is the gross redundancy.  Wakefulness is not the function of a single ascending arousal 
pathway and none of the multiple wakefulness-promoting brain sites is necessary for the 
generation of arousal. 
 
A recently discovered part of the wake-promoting system resides in the perifornical 
area of the lateral hypothalamus (LH) where cells are producing the peptide orexin.  
Orexinergic neurons diffusely project and innervate the cerebral cortex and also excite other 
arousal centers, such as the basal forebrain, locus ceruleus, tuberomamillary nucleus and raphe 
nucleus.  Lack of the orexin peptide or functional orexin receptors result in narcolepsy in 
humans, dogs and mice.  Orexin-producing neurons are also part of a food intake regulatory 
circuit in the hypothalamus.  Orexin, as the name implies, also promotes eating.  
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Hypothalamic ghrelin-, neuropeptide Y (NPY)- and orexinergic cells form a well-
characterized neuronal network.  Increased activity of the circuit stimulates feeding. 
 
The hypothalamic ghrelin – NPY – orexin circuit 
 
Ghrelin-producing neurons are most abundantly present in the arcuate nucleus 
(ARC) but also found in the LH, paraventricular nucleus (PVN), the hypothalamic area 
adjacent to the ARC, ventromedial hypothalamic nucleus (VMH), dorsomedial hypothalamic 
nucleus (DMH) and PVN with overlapping projections from the suprachiasmatic nucleus and 
the ventral lateral geniculate nucleus of the thalamus.  Bidirectional synaptic connections exist 
among ghrelin-, NPY and orexin-producing neurons (Figure 1).  In the ARC, ghrelin 
stimulates the production and release of NPY.  In the LH, ghrelin activates orexinergic 
neurons directly and also indirectly via NPY.  Ghrelin stimulates CRH neurons by promoting 
the release of NPY from axon terminals in the PVN. 
 
The activation of the circuit leads to increased food intake whereas its suppressed 
activity results in decreased eating.  A key component of the circuit, orexin, is shared by at 
least two systems, an arousal- and a food intake-promoting system.  Mounting evidence 
suggests the existence of neuronal circuits shared by the regulation of sleep-wake activity and 
feeding/metabolism.  Based on the localization and organization of the ghrelin – NPY – orexin 
circuit we hypothesized that this circuit is shared by feeding and arousal.  The objective of our 
work was to study the role of the hypothalamic ghrelin – NPY – orexin circuit in sleep.  In a 
series of experiments, we determined the diurnal rhythm of plasma and hypothalamic ghrelin 
levels, the dependency of this rhythm on sleep-wake activity and the sleep-wake activity-
modulating effects of central injections of ghrelin and NPY in rats. 
 
 
EXPERIMENTAL DESIGN 
 
Experiment 1.  Diurnal rhythms of sleep, feeding activity, plasma leptin, ghrelin and 
hypothalamic ghrelin levels rats. 
Baseline sleep-wake and feeding activity were recorded for 3 days.  For the test days, rats were 
divided into three groups (n = 7-12) and subjected to three different experimental 
manipulations. 
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Experiment 1/a.  The access to the feeding tubes was continuous. 
Experiment 1/b.  Rats were kept on a restricted feeding schedule with ad libitum access to 
the feeder only during the light period for at least 3 wk before recordings. 
Experiment 1/c.  On the experimental day, rats were sleep deprived by gentle handling in 
the first 5 h of the light period.  The rats stayed in their home cage, and whenever 
behavioral or EEG signs of sleep were observed, they were aroused by knocking on the 
cage or lightly touching them.  After sleep deprivation, the animals remained in their home 
cages and were allowed to sleep ad libitum.  Food was continuously available during the 
sleep deprivation and recovery periods.  The animals were sacrificed by guillotine at the 
following time points: 1 and 5 h after the beginning of sleep deprivation (i.e., 1 and 5 h 
after light onset) and 4, 8, 12, and 16 h after the end of sleep deprivation (i.e., 9, 13, 17 and 
21 h after light onset).  Blood and hypothalamus were collected from each animal for 
hormone assays.  At each time point, control rats not subjected to sleep deprivation, were 
also sacrificed. 
 
 
Experiment 2.  The effects of icv administration of ghrelin on sleep in rats. 
Experiment 2/a.  The effects of three doses of ghrelin, 0.2 μg (n = 11), 1 μg (n = 8), and 5 
μg (n = 13) on sleep were tested.  Injections were done 10-15 minutes before dark onset. 
Experiment 2/b.  Three separate groups of rats received the same doses of ghrelin (n = 8, 
n = 6, n = 12, respectively) before light onset.  In both Experiment 2/a and 2/b, two 
conditions were used: a baseline day when 2 μl of isotonic NaCl was administered and the 
experimental day when ghrelin was injected.  The order of the baseline and experimental 
days was randomly chosen.  Each rat was recorded from light onset or dark onset, 
respectively, for 12 hours after injections.  Food intake after the light onset administration 
of 1 µg ghrelin was also measured in the same group of animals 4 days after the sleep 
studies. 
Experiment 2/c.  Rats were allowed to eat only during the light phase.  Food pellets were 
removed at light onset and returned 12 hours later at dark onset, each day for at least 10 
days before recording.  Sleep-wake activity was recorded for 12 hours on 2 consecutive 
days: a baseline day when isotonic NaCl was administered and an experimental day when 
1 μg ghrelin was injected.  The order of the baseline day and experimental day was 
balanced. 
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Experiment 3.  The effects of hypothalamic microinjections of ghrelin on sleep and food 
intake in rats. 
Rats with bilateral microinjection cannulae in the LH or medial preoptic area (MPA) and 
unilateral cannula in the PVN were used in the experiment.  On the control day, the animals 
received 100 nl pyrogen-free isotonic NaCl; on the experimental day, they were injected with 
ghrelin (0.04 μg, 0.2 μg, or 1 μg/injection site, 12, 60, and 300 pmol, respectively; dissolved in 
100 nl isotonic NaCl).  The order of the control and experimental days was counterbalanced.  
Food and water were provided ad libitum during the entire recording period.  Food intake was 
measured 1 hour after injections.  Sleep was recorded for 23 h starting from the beginning of 
light period. 
 
Experiment 4.  The effects of NPY on sleep and food intake in rats 
Experiment 4/a.  The three doses of NPY (0.4 μg, n = 8, 2 μg, n = 9, and 10 μg, n = 8) on sleep 
were tested.  Rats received icv injection of pyrogen-free isotonic NaCl on the baseline and 
NPY on the experimental day 10-15 min before light onset.  All injections were given in a 
volume of 4 μl.  The order of the baseline and experimental days was randomly chosen.  In 
Experiment 4/b, rats (n = 8) received bilateral microinjection of 2 μg NPY in a volume of 
0.2 μl into the LH on the test day and equal volumes of isotonic NaCl on the control day. 
 
 
RESULTS 
 
Experiment 1/a.  Diurnal rhythms of sleep, feeding activity, plasma leptin, ghrelin and 
hypothalamic ghrelin levels in free-feeding rats. 
The diurnal rhythm of sleep-wake activity displayed the normal patterns of rats with more 
time spent in NREMS and REMS during the light phase and less during the dark.  Free-
feeding rats ate mostly at night; only a small fraction of the total daily feeding activity 
occurred during the light period.  Dark onset was associated with increased eating; 
13.9 ± 1.24% of the daily feeding activity occurred during the first hour of the dark period.  
Feeding activity bouts recurred throughout the night.  Plasma leptin and ghrelin displayed 
distinct diurnal rhythms with their peak values occurring at opposite times of the day.  The 
leptin maximum followed the dark onset-elicited eating peak and occurred 5 hours after dark 
onset.  The ghrelin peak preceded the eating peak and occurred 5 hours after light onset when 
leptin dropped to its diurnal trough value.  Hypothalamic ghrelin showed modest oscillations 
 6 
with a rise after the plasma ghrelin peak and a second increase toward the end of the dark 
period. 
 
Experiment 1/b.  Diurnal rhythms of sleep-wake activity, plasma leptin and ghrelin and 
hypothalamic ghrelin levels in feeding-restricted rats. 
Restriction of feeding to the light period significantly altered the sleep-wake activity of rats.  
NREMS decreased by 11% during the light period and increased by 10% during the dark.  The 
normal diurnal rhythm with more NREMS during the day was maintained.  Restricted feeding 
fundamentally altered the diurnal rhythm of REMS.  REMS decreased throughout the light 
period and increased in the dark period, resulting in more REMS at night than during the day.  
The daily, 24-hour total amount of NREMS and REMS did not change.  During the feeding 
restriction, feeding activity was the highest at the beginning of the light period.  Feeding 
activity in the first hour of the light period was 31.8 ± 2.2% of the total daily activity, and this 
value was significantly higher than the feeding activity of rats on ad libitum feeding in the first 
hour of the dark.  Feeding activity decreased after the first hour of the light period but 
remained significantly elevated compared to the baseline conditions for the rest of the light 
period.  In response to restricted feeding, diurnal rhythms of ghrelin and leptin reversed in 
such a way that they maintained their relationship with respect to one another and to feeding 
activity.  The ghrelin peak continued to precede the major feeding peak, which was now in the 
first hour of the light, and thus the ghrelin maximum was observed at the end of the dark 
period.  The leptin peak followed the major feeding activity peak, and it occurred during the 
day between hours 5 and 9 after light onset.  The concentrations calculated for 24 hours 
increased significantly for both plasma leptin and ghrelin and hypothalamic ghrelin. 
 
Experiment 1/c.  Rhythms of plasma leptin, ghrelin and hypothalamic ghrelin levels after 
5 hours of sleep deprivation. 
Five hours of sleep deprivation was followed by significant increases in the duration of both 
NREMS and REMS.  NREMS time increased immediately after sleep deprivation and 
remained elevated during the dark period.  Increases in REMS occurred towards the end of the 
light and during the dark period.  Feeding activity was significantly stimulated during sleep 
deprivation.  During the 5 hours of sleep deprivation, 11.1 ± 2.9% of the 24-hour feeding 
activity occurred.  Sleep deprivation did not alter plasma concentration of leptin.  In contrast, 
plasma ghrelin increased significantly in the first hour of sleep deprivation.  Hypothalamic 
ghrelin was highly responsive to sleep deprivation, displaying statistically significant biphasic 
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variations.  Ghrelin contents of the hypothalamus increased significantly during sleep 
deprivation and dropped below baseline after sleep deprivation. 
 
Experiment 2/a.  The effects of dark onset administration of ghrelin on sleep in rats. 
One μg ghrelin induced significant decreases in NREMS and REMS in hours 1 and 2.  In 
hours 3-12 after injection, sleep returned to baseline.  Five μg ghrelin had a biphasic effect on 
NREMS.  In the first 2 hours after injection NREMS decreased while NREMS was increased 
during the rest of the recording period.  Similar tendencies in REMS were observed but the 
changes only reached the level of significance in hours 1 and 2. 
 
Experiments 2/b and 2/c.  The effects of light onset administration of ghrelin on sleep, 
activity and food intake in free-feeding and feeding restricted rats. 
Ghrelin induced significant dose-dependent changes in wakefulness, NREMS and REMS in 
hours 1 and 2 after injection.  One μg ghrelin had a biphasic effect on wakefulness and 
NREMS.  Wakefulness was significantly increased in hours 1 and 2 after injection, 
simultaneously, NREMS and REMS were suppressed.  During hours 3 to 12, NREMS was 
elevated.  One μg ghrelin increased wakefulness in feeding restricted rats, i.e., rats with no 
access to food after ghrelin injection, and induced significant decreases in NREMS in hour 1.  
In the following hours, NREMS did not differ from baseline values.  REMS did not change in 
the first 2 hours but from hours 3 to 12 a significant decrease was observed.  The 1 μg ghrelin-
induced NREMS decrease in hours 1 and 2 was significantly higher in free-feeding rats than in 
feeding restricted animals.  Sleep suppression after ghrelin administration was accompanied 
by behavioral activation.  Rats were restless throughout the 60-minute observation period; 
their behavior included increased locomotor activity, eating, drinking, grooming and 
exploration.  The first bout of eating was observed in 10 minutes after the injection and eating 
continued throughout the first hour of the light period resulting in higher food intake than after 
the control injection. 
 
Experiment 3/a.  The effects of ghrelin microinjection into the LH on sleep-wake activity, 
EEG and food intake in rats. 
Administration of 0.2 μg ghrelin significantly increased the time spent in wakefulness and 
decreased the time in NREMS and REMS.  The effects on wakefulness and NREMS were 
confined to the first two hours of the recording period, while REMS changes were significant 
in hours 2 and 3.  In hours 4 and 5 after injection, EEG slow-wave activity (SWA) was 
 8 
significantly elevated.  Injection of 0.2 μg ghrelin significantly increased the 1-hour food 
intake of the rats from a baseline of 0.65 ± 0.56 g/kg BW to 6.36 ± 1.16 g/kg BW after ghrelin 
treatment.  Similarly to the middle dose, 1 μg ghrelin injection increased wakefulness and 
decreased NREMS in the first two hours after ghrelin treatment.  EEG SWA was significantly 
attenuated in the first hour following ghrelin injection.  One μg ghrelin significantly stimulated 
the 1-hour food intake of the rats (0.25 ± 0.14 g/kg BW after control treatment vs. 
7.02 ± 1.75 g/kg BW after ghrelin treatment). 
 
Experiment 3/b.  The effects of ghrelin microinjection into the MPA of the hypothalamus on 
sleep-wake activity, EEG and food intake in rats. 
The middle dose of ghrelin, 0.2 μg, induced a significant increase in wakefulness at the 
expense of both NREMS and REMS in the first hour of the recording period.  EEG SWA was 
significantly increased beginning from the fourth hour.  Injection of 0.2 μg ghrelin was 
followed by a significant increase in food intake (5.01 ± 0.53 g/kg BW vs. 0.45 ± 0.23 g/kg 
BW after saline injection).  The highest dose, 1 μg ghrelin induced a statistically significant 
increase in wakefulness and decrease in NREMS and REMS.  The effects were confined to the 
first hour of the recording period.  The NREMS changes in the first hour were accompanied by 
a significant decrease in EEG SWA.  The initial decrease in EEG SWA was followed by an 
increase beginning from the fourth hour.  Food intake was significantly stimulated by 1 μg 
ghrelin injection (0.74 ± 0.34 g/kg BW on the control day and 7.44 ± 1.26 g/kg BW on the 
treatment day). 
 
Experiment 3/c.  The effects of ghrelin microinjection into the PVN of the hypothalamus on 
sleep-wake activity, EEG and food intake in rats. 
Injection of 0.2 μg ghrelin in the PVN did not change the time spent awake, in NREMS or 
REMS and there was no significant effect on EEG SWA.  Food intake significantly increased 
from a baseline of 0.82 ± 0.35 g/kg BW to 4.52 ± 1.14 g/kg BW in response to 0.2 μg ghrelin 
injection.  One μg ghrelin induced a statistically significant increase in time spent awake in the 
first hour after injection, which was accompanied by a significant decrease in NREMS.  EEG 
SWA did not change in response to 1 μg ghrelin injection.  Injection of 1 μg ghrelin into the 
PVN of the rats induced a significant, about 4-fold increase, in food intake. 
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Experiment 4/a.  The effects of icv administration of NPY on sleep-wake activity and food 
intake in rats. 
Administration of 2 μg NPY induced significant increase in wakefulness and decrease in both 
NREMS and REMS.  In first hour after injection, NREMS decreased from a baseline of 
26.6 ± 2.2 min to 12.6 ± 2.3 min in response to NPY treatment.  REMS virtually disappeared 
in hour 1 after NPY injection.  The reduced time spent in sleep mainly resulted from a 
significant decrease in the average duration of NREMS episodes and a significant decrease in 
the number of REMS episodes.  The EEG SWA was not altered by 2 μg NPY.  Food intake in 
the first hour after NPY injection increased significantly compared to baseline.  Similarly to 
the middle dose of NPY, 10 μg injection of NPY was followed by a significant increase in 
wakefulness and decrease in both NREMS and REMS amount.  Post hoc analyses showed 
significant suppression in NREMS in hour 1.  The NREMS decrease may be due to the 
significant decrease in the number of NREMS episodes.  In hour 1, on the baseline day, rats 
had already minimal amount of REMS, and on the NPY day they had no REMS at all.  
Injection of 10 μg NPY did not change the EEG SWA.  The highest dose of NPY significantly 
increased the food intake in the first hour after injection. 
 
Experiment 4/b.  The effects of LH administration of NPY on sleep-wake activity and food 
intake in rats. 
Wakefulness was significantly elevated in the first hour after the injections.  The amounts of 
NREMS and REMS were significantly decreased.  NREMS episode number significantly 
decreased in hour 1 and there was a tendency toward decrease in average NREMS episode 
duration, as well.  EEG SWA increased in response to the injection starting from hour 3, 
however, post hoc analyses did not show significance in any particular hour.  Food intake was 
significantly enhanced by LH injection of NPY. 
 
 
DISCUSSION 
 
The major findings of the experiments presented here are the following.  Plasma 
ghrelin and leptin levels and hypothalamic ghrelin content display marked diurnal rhythm 
associated with feeding and sleep-wake activity.  In free feeding rats, plasma and 
hypothalamic ghrelin contents reach their highest levels before the onset of the dark phase 
preceding the peak in feeding activity.  During the dark, ghrelin levels gradually decrease and 
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stay low for the rest of the dark and beginning of the light period.  Diurnal rhythm of plasma 
leptin shows opposite pattern of ghrelin’s.  Food restriction to the light period reverses REMS, 
plasma ghrelin and leptin rhythms and sleep deprivation increases plasma and hypothalamic 
ghrelin levels.  Intracerebroventricular injection of ghrelin induces dose-dependent and 
immediate increases in wakefulness, food intake and feeding behavior, with the concomitant 
suppression of NREMS and REMS.  Microinjections of ghrelin into the LH, MPA and PVN 
mimic the effects of the icv ghrelin treatment.  Intra-LH microinjections have the most robust 
and long-lasting effect among the hypothalamic nuclei tested.  The effects of icv and intra-LH 
injections of NPY on sleep are similar to those of ghrelin’s. 
 
Our findings are in agreement with previous studies reporting that icv 
administration and microinjections of ghrelin into the LH, MPA and PVN increase food 
intake.  The feeding-inducing activity of ghrelin was sufficiently strong that it was able to 
stimulate food intake at the beginning of the light period when rats are usually satiated and 
sleep pressure is the highest. 
 
Our studies are the first to test the effects of centrally administered ghrelin on 
vigilance.  Icv and hypothalamic microinjections of ghrelin at light onset induced consistent, 
robust and dose-dependent increases in wakefulness and suppression of NREMS and REMS in 
rats.  This is in agreement with the hypothesis that ghrelin may serve as a signaling molecule 
in central arousal systems.  Previous studies on the effects of systemically administered 
ghrelin did not yield to consistent findings.  In humans, increased and decreased sleep and no 
effect on sleep have been reported while intraperitoneal administration of ghrelin at dark onset 
increased NREMS in mice.  The difference between our findings of consistent wake-
promoting effects of ghrelin in rats and the reported somnogenic effects in humans and mice 
may reflect true species specificity in the effect or may be due to other differences in the 
experimental conditions, such as the route of administration or the timing of the treatment.  
Our findings that ghrelin induces wakefulness are consistent with previous studies showing 
prompt increases in wakefulness at the expense of both NREMS and REMS after intravenous 
injections of ghrelin in rats.  When we injected ghrelin at light onset, the sleep suppressive 
effect was robust, sleep almost completely disappeared in the first hour of the light period in 
response to 1 µg ghrelin.  Ghrelin-induced changes in sleep duration after icv injections had a 
biphasic pattern.  The immediate effect is a prominent dose-dependent increase in wakefulness 
which is followed by increases in NREMS during hours 3-12 post-injection.  We posit that the 
primary effect of ghrelin is to stimulate wakefulness.  It is possible that increases in NREMS 
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are secondary to sleep loss and/or increased eating in the first hour(s).  Sleep loss leads to 
subsequent homeostatic increases in sleep while eating is known to elicit postprandial 
increases in sleep.  The finding, that the secondary increases in NREMS are absent in rats that 
were not allowed to eat after ghrelin treatment strongly suggests that increased feeding could 
be, at least in part, responsible for the delayed sleep responses.  The mechanism of the 
wakefulness-promoting effects of ghrelin in rats is unknown.  Ghrelin’s food intake-promoting 
effect is mediated by a central action involving primarily the NPY-signaling pathway in the 
ARC of the hypothalamus.  We hypothesized that ghrelin’s wakefulness-promoting effect is 
also mediated by central mechanisms. 
 
The increased sensitivity/high responsiveness of hypothalamic ghrelin levels to 
sleep deprivation supports this notion.  Plasma ghrelin level was also elevated during sleep 
deprivation and returned to normal during the rebound sleep.  A strong stimulus for ghrelin 
secretion is fasting.  In our sleep deprivation experiments, however, the animals were not 
fasted; feeding activity was even increased during the sleep deprivation period.  In response to 
restricted feeding, rhythm of plasma leptin levels shifted but remained coupled to the feeding 
activity.  The light-dark reversal in the diurnal rhythms of ghrelin and leptin by restricted 
feeding is mirrored by similar fundamental changes in the diurnal distribution of REMS. 
 
Ghrelin receptors have been found in various hypothalamic structures implicated in 
sleep-wake regulation such as anteroventral preoptic nucleus, anterior hypothalamic area, 
SCN, anterolateral hypothalamic nucleus, ARC, PVN, and TMN.  To test possible 
hypothalamic sites that may mediate ghrelin’s wake-promoting action we characterized sleep 
and food intake after intrahypothalamic ghrelin microinjections.  Ghrelin injection into the 
LH, MPA or PVN increased the amount of wakefulness in the first hour after injection.  
Ghrelin-induced increase in wakefulness was most marked when the peptide was 
microinjected into the LH.  The effects of icv injection of 1 μg ghrelin were similar to those 
seen after LH microinjection of 0.2 μg. 
 
There are several possible mechanisms that may mediate the wake-promoting 
effect of ghrelin; these mechanisms are summarized on Figure 1.  One possibility is that 
ghrelin activates orexinergic and NPY-ergic arousal mechanisms.  Ghrelin-containing neurons 
innervate orexin-producing cells in the LH and icv or local application of ghrelin into the LH 
of rats activates orexin neurons.  The stimulatory effect of ghrelin on feeding is known to be 
mediated through NPY-ergic mechanisms in the ARC.  In the PVN, the presynaptic terminals 
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Figure 1.  Schematic drawing of the hypothalamic ghrelin-NPY–orexin circuit with 
possible pathways mediating the wakefulness-promoting effects of ghrelin and NPY.  
Hypothalamic ghrelin-, orexin-, and NPYergic neurons form a well-characterized circuit that 
is implicated in the regulation of food intake.  We posit that the activation of the same circuit 
promotes wakefulness.  Ghrelin elicits wakefulness when injected into the cerebral ventricle, 
LH, PVN, or MPA.  Ghrelin activates orexinergic cells in the LH and NPY-containing cells 
in the ARC.  In the PVN, ghrelin facilitates CRH release indirectly through the stimulation of 
NPY-ergic neurons.  In the MPA, ghrelin stimulates NO formation.  Hypothalamic orexin, 
CRH and NO are all known to stimulate wakefulness and are possible outputs of the ghrelin-
orexin-NPY circuit. 
of NPY-producing neurons express GHS-R and ghrelin-positive neuronal projections from the 
ARC stimulate NPY release.  Another possibility is that ghrelin acts through the activation of 
the hypothalamic--pituitary--adrenal axis; corticotrop-releasing hormone (CRH) release is 
stimulated by ghrelin in the PVN and CRH is known to inhibit sleep. 
Previous studies concerning NPY’s sleep-modulating effect did not yield consistent 
results.  In our experiments, when NPY was injected at light onset, the sleep suppressive 
effects were robust; both NREMS and REMS significantly decreased in the first hour of the 
light period, REMS practically disappeared.  The decrease in NREMS amount in the first hour 
after the injection is clearly reflected in the decreased total number of NREMS episodes.  It is 
also possible that NPY’s stimulatory action on orexinergic cells in the LH mediates the wake-
promoting effect of NPY.  This notion is supported by our observation that NREMS decreased 
in response to LH injection of NPY.  A reciprocal relationship exists between NPY and 
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Figure 2.  Food intake and wakefulness during the first hour of the dark phase under 
normal conditions and in the first hour of light after icv administration of ghrelin and 
NPY in rats.  Central injections of ghrelin and NPY stimulates eating and wakefulness in 
the light period.  These changes are characteristic of and spontaneously occurring during 
the first hour of the dark phase.
orexinergic neurons.  Icv administration of orexins stimulates NPY expression in the ARC.  
Orexinergic axon terminals, originating from the LH, form synapses on NPY-immunoreactive 
cells in the ARC.  Orexin receptors are present on NPY neurons in the ARC.  The feeding 
stimulatory effect of orexin may be mediated, at least partly, by NPY, since orexin-induced 
feeding is inhibited by pretreatment with NPY receptor antagonists.  Conversely, orexin 
antiserum significantly attenuates the feeding response to NPY.  In addition to orexinergic 
neurons, NPY activates CRH release and increases CRH gene expression in the PVN and 
CRH is known to inhibit sleep. 
 
 
CONCLUSIONS AND PERSPECTIVES 
 
In summary, the sleep-suppressing and food intake-promoting activities of central 
NPY, ghrelin, and orexin in rats are strikingly similar (Figure 2).  The first hours of the dark, 
behav-iorally active period in rats are characterized by increased time spent awake, increased 
duration of the individual wake episodes, and increased eating activity.  We named this 
behavioral pattern “dark onset syndrome”.  Central administration of ghrelin or NPY elicits all 
components of the dark onset syndrome.  We posit that the increased feeding activity and the 
stimulation of wakefulness are two parallel outputs of the activation of the same hypothalamic 
orexin-ghrelin-NPY circuit. 
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Food intake occurs at environmentally advantageous times and in response to 
homeostatic needs.  While feeding and sleep are mutually exclusive behaviors, wakefulness, 
with increased sensory awareness and motor activity, is a prerequisite for successful feeding.  
The diurnal distribution of wakefulness and feeding are highly species dependent.  Humans 
consolidate waking and feeding cycles during the daytime.  Nocturnal rodents, such as rats and 
mice, are awake and feed primarily at night.  From an evolutionary perspective, during 
shortages of food availability, central mechanisms promoting wakefulness, therefore feeding 
opportunities during the appropriate circadian phase are crucial for survival.  Mounting 
evidence supports the idea that mechanisms responsible for feeding behavior and the control 
of sleep-wake activity are coordinated by partly overlapping hypothalamic neuronal systems.  
These systems integrate information about the energy status of the body through hunger, 
adiposity, and satiety signals and metabolic and neural signals.  We hypothesize that the 
hypothalamic ghrelin – NPY - orexin circuit is a major the integrative center.  It receives and 
integrates metabolic, circadian, and visual signals.  The activation of the circuit has two main 
parallel outputs: increased wakefulness and increased feeding activity. 
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